Marshall Wace
CSTL icon

Marshall Wace’s Castle Biosciences CSTL Stock Holding History

Marshall Wace’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-220,797
Closed -$6.3M – 2645
2024
Q3 		$6.3M Buy
220,797
+8,761
+4% +$223K 0.01% 910
2024
Q2 		$4.62M Buy
212,036
+114,104
+117% +$2.54M 0.01% 1025
2024
Q1 		$2.17M Buy
97,932
+53,032
+118% +$1.15M ﹤0.01% 1325
2023
Q4 		$969K Buy
+44,900
New +$790K ﹤0.01% 1489
2022
Q3 		– Sell
-10,400
Closed -$228K – 3406
2022
Q2 		$228K Buy
+10,400
New +$242K ﹤0.01% 3128
2021
Q1 		– Sell
-19,995
Closed -$1.34M – 2530
2020
Q4 		$1.34M Buy
19,995
+15,468
+342% +$838K 0.01% 1090
2020
Q3 		$234K Sell
4,527
-34,692
-88% -$1.54M ﹤0.01% 1422
2020
Q2 		$1.48M Buy
39,219
+24,188
+161% +$826K 0.01% 890
2020
Q1 		$448K Buy
+15,031
New +$454K ﹤0.01% 1000

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Marshall Wace's CSTL Position: Q4 2024 in Review

Marshall Wace sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 220,797 shares — an estimated $6.3M sold.

Marshall Wace first reported a position in CSTL in Q1 2020 and held it in 9 quarters. The position peaked at $6.3M in Q3 2024. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

  • Marshall Wace reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
  • Marshall Wace sold 220,797 Castle Biosciences shares in Q4 2024, an estimated $6.3M.
  • Marshall Wace first reported a position in Castle Biosciences in Q1 2020 and held it in 9 quarters.
  • Marshall Wace's Castle Biosciences position peaked at $6.3M in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.